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A case of autoimmune hemolytic anemia with 
anti-D specificity in a 1-year-old child
R.S. Bercovitz, M. Macy, and D.R. Ambruso
Although antibodies to antigens in the Rh blood group system 
are common causes of warm autoimmune hemolytic anemia, 
specificity for only the D antigen is rare in autoimmune hemolysis 
in pediatric patients. This case reports an anti-D associated 
with severe hemolytic anemia (Hb = 2.1 g/dL) in a previously 
healthy 14-month-old child who presented with a 3-day history 
of low-grade fevers and vomiting. Because of his severe anemia, 
on admission to the hospital he was found to have altered 
mental status, metabolic acidosis, abnormal liver function tests, 
and a severe coagulopathy. He was successfully resuscitated 
with uncrossmatched units of group O, D– blood, and after 
corticosteroid therapy he had complete resolution of his anti-D-
mediated hemolysis. Immunohematology 2013;29:15-18.
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Autoimmune hemolytic anemia (AIHA) is the pathological 
destruction of red blood cells (RBCs) by antibodies produced 
against self-erythrocyte surface antigens. Its prevalence is 
estimated to be approximately 1 to 3 per 100,000 per year, 
although it may be lower in pediatric patients.1–4 Warm AIHA 
is usually caused by immunoglobulin G (IgG) antibodies that 
bind to RBC antigens and result in erythrophagocytosis by 
splenic macrophages or hepatic Kupffer cells. In many cases, 
antigen specificity cannot be determined, or patients express 
pan-reactivity across antigen groups. However, there have 
been reports of specificity to as many as 50 RBC antigens 
with anti-e being one of the most common specificities cited 
in reviews.4–6
AIHA can be either a primary or a secondary disease, 
usually as a result of an underlying autoimmune disease, 
primary immunodeficiency, or lymphoid malignancy; it can 
present in a known primary process or as part of its initial 
presentation.4,7,8 In adult patients primary AIHA represents 
approximately 60 percent of cases.9 In case series of pediatric 
patients, the proportion of patients with primary AIHA 
has ranged from 7 to 64 percent.4,5,10 This case of AIHA is 
unusual because of the D specificity of the autoantibody and 
its occurrence in a 14-month-old child without an underlying 
immune or autoimmune disorder and with no long-term 
sequelae.
Case Report
A previously healthy 14-month-old white male born 
after a term pregnancy without perinatal problems and 
with no prior history of blood transfusion presented to the 
emergency department with lethargy and jaundice. He had 
a history of low-grade fevers, vomiting, and fatigue for 3 
days before presentation. On the day of admission he was 
noted to have occasional episodes of shallow breathing with 
decreased responsiveness. His vital signs showed he was 
tachycardic, normotensive, and not hypoxic. He was noted to 
be pale, jaundiced, and responsive to painful stimulus only. 
In addition, he was found to have an intermittent gallop and 
hepatosplenomegaly.
His initial blood work showed he was severely anemic 
with a hemoglobin (Hb) of 2.1 g/dL, hematocrit (Hct) of 7.1 
percent, and an elevated reticulocyte count of 32 percent. His 
white blood cell count was elevated, and his platelet count was 
normal. The pertinent laboratory evaluations are summarized 
in Table 1. In addition to his severe anemia, the patient had 
a bilirubin that was greater than 3 times the upper limit of 
normal and a lactate dehydrogenase, which is a marker for 
rapid cell turnover, that was almost 6 times the upper limit of 
normal. The results were consistent with the diagnosis of an 
acute hemolytic anemia.
Further laboratory testing demonstrated significant 
end-organ ischemia secondary to his severe anemia. He was 
acidotic on admission, with a pH of 7.19. He had evidence of 
prerenal insufficiency and hepatic dysfunction with elevated 
hepatocellular enzymes. Although he did not have any 
clinical signs of bleeding, he had a prolonged prothrombin 
time, but a normal partial thromboplastin time. Further 
evaluation of coagulation factors demonstrated a deficiency 
in factors II, V, and VII, an elevated factor VIII, and normal 
fibrinogen. His D dimer was 1390 ng/mL. Although there 
was evidence of activation of coagulation, the patient did not 
have severe consumption, and his coagulopathy was most 
likely attributable to decreased hepatic synthesis. Vitamin K 
deficiency could not be documented.
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He was resuscitated with both crystalloid fluids and 
emergency units of unmatched, group O, D– packed RBCs. 
After this resuscitation the patient’s mental status and 
cardiovascular status improved. His renal and liver function 
tests improved, and he had prompt resolution of his metabolic 
acidosis.
Further testing showed that the patient was group B, D+ 
with warm-reacting autoantibodies. His direct antiglobulin 
test (DAT) was 2+ positive for IgG, and an eluate from the cells 
demonstrated anti-D specificity and no reactivity with D+ 
LW– RBCs. Extended Rh phenotype by serology indicated that 
the patient was D+, C–/c+, E+/e– (likely R2R2); however DNA 
testing revealed that the patient’s genotype was D heterozygote, 
C–/c+, and E+/e+ (likely R2r). There was no evidence of anti-
C/c or anti-E/e alloantibodies or autoantibodies. Sequencing 
of his RHD gene showed he was negative for the 
RHD-inactivating pseudogene and had none of 
the 18 most common partial D genotypes. The 
discrepancy between his positive e genotype and 
negative phenotype for e is likely caused by an 
altered RHCE gene, although complete sequencing 
could not be performed.
After his initial resuscitation, the patient’s 
hemoglobin remained stable with no additional 
evidence of hemolysis, and he did not require 
any additional RBC transfusions. On the day of 
admission, he was started on a 10-day course 
of prednisone (2 mg/kg per day) and was 
successfully tapered off the medication without 
recrudescence of his hemolysis. Infectious disease 
testing was performed, including a respiratory 
virus direct stain for adenovirus, influenza A and 
B, parainfluenza 1 through 3, and respiratory 
syncytial virus, which was negative. There was 
no evidence of current or prior infection with 
Epstein-Barr virus. The patient had no underlying 
conditions such as another autoimmune disorder 
(negative antinuclear antibody), immunodeficiency 
(normal serum immunoglobulins), or malignancy, 
making this a primary AIHA.
Samples from the patient exhibited a weakly 
positive DAT for 2 to 3 months after his initial 
presentation. Subsequently, the DAT became 
negative, and he had complete resolution of his 
hemolysis 1 year after his initial presentation 
without evidence of any autoimmune or immune 
disorders.
Discussion
AIHA is caused by antibodies to a specific antigen 
on the patient’s own erythrocytes, resulting in either 
intravascular or extravascular hemolysis. Warm AIHA is 
caused by IgG antibodies and results in antibody-mediated 
erythrophagocytosis by splenic macrophages. Cold AIHA is 
caused by IgM antibodies and results in intravascular hemolysis 
secondary to complement fixation on the RBC surface. The 
thermal amplitude of the antibodies determines their clinical 
significance; cold agglutinins that are reactive at temperatures 
lower than body temperature are generally of little clinical 
significance. Biphasic IgG antibodies that bind RBCs at colder 
temperatures and then fix complement in warmer temperatures 
cause paroxysmal cold hemoglobinuria (PCH).
Table 1. Selected abnormal laboratory values in this patient consistent with a 
brisk hemolytic process and end-organ ischemia caused by severe anemia
Laboratory test Patient’s results Normal range
Complete blood count
White blood cells (WBC) 39.4 × 103/µL 5–13 × 103/µL
Hemoglobin (Hb) 2.1 g/dL 9.5–14 g/dL
Hematocrit (Hct) 7.1% 30–41%
Platelet count 376 × 103/µL 150–500 × 103/µL
Reticulocyte count 32% 0.56–2.72%
Blood chemistries
Venous blood gas
pH 7.19 7.32–7.42 
PCO2 19 mm Hg 40–50 mm Hg
Bicarbonate (HCO3) 7 mEq/L 22–25 mEq/L
Glucose 36 mg/dL 60–105 mg/dL
Blood urea nitrogen (BUN) 50 mg/dL 6–17 mg/dL
Creatinine 0.7 mg/dL 0.2–0.6 mg/dL
Lactate dehydrogenase (LDH) 2042 U/L 150–360 U/L
Liver function tests
Bilirubin (total) 3.7 mg/dL 0.2–1.2 mg/dL
Aspartate transaminase (AST, SGOT) 1388 U/L 20–60 U/L
Alanine transaminase (ALT, SGPT) 689 U/L 0–33 U/L
Coagulation tests
Prothrombin time (PT) 49 seconds 10.8–13.8 seconds
Partial thromboplastin time (PTT) 27 seconds 25.4–35 seconds
Factor II 38% 50–150%
PIVKA II 0 U/dL 0 U/dL
Factor V 14% 63–116%
Factor VII 4% 52–120%
Factor VIII 363% 58–132%
Fibrinogen 276 mg/dL 202–404 mg/dL
D dimer 1390 ng/mL >255 ng/mL
PIVKA II =protein-induced by vitamin K absence or antagonist II.
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AIHA with anti-D specificity
The incidence of both warm and cold AIHA increases 
with patient age. But in pediatric patients the highest incidence 
of cold AIHA, including cold agglutinin syndrome and PCH, 
is in patients younger than the age of 4, likely because of their 
association with common childhood infections such as viral 
respiratory infections and Mycoplasma pneumoniae.9 In most 
case series, warm AIHA constitutes about 60 percent of the 
cases in pediatric patients.10 Some series report that primary 
AIHA is more common, whereas others demonstrate that 
secondary AIHA is more common in pediatric patients.5,9,10
One of the largest series showed that the majority of 
cases of AIHA are caused by warm antibodies, 64 percent, 
versus 26 percent attributable to cold antibody and 10 percent 
attributable to mixed antibodies (n = 100).10 This series also 
demonstrated that approximately half of the patients (54%) had 
an underlying disease process such as autoimmune disease, 
idiopathic thrombocytopenia, neoplasia, or hemoglobinopathy, 
whereas the remaining 46 percent of patients had primary 
(idiopathic) AIHA. The most common autoimmune disorders 
associated with AIHA include lupus, Evan’s syndrome, 
autoimmune lymphoproliferative syndrome (ALPS), and 
other immunodeficiencies. The majority of patients with warm 
antibody disease, 59 percent (38/64), had primary AIHA,10 
similar to a series of 26 children in India that showed that 65 
percent had primary AIHA.11 Children with primary AIHA 
are more likely than adults to have a self-resolving, relatively 
short course (less than 6 months). Patients who present at 
younger than 2 years and older than 12 years are at risk for a 
chronic course.12
The discrepancy between the patient’s e negative 
phenotype and e positive genotype likely represents an altered 
RHCE gene. This altered gene may place the patient at a higher 
risk of developing alloantibodies to the e antigen; however, it 
should not play a role in the development of autoantibodies 
to D. D is the most immunogenic antigen when development 
of alloantibodies occurs after an exposure; however, it is 
not commonly associated with autoantibody development. 
Antibodies against antigens in the Rh system, such as anti-e, 
anti-E, and anti-c, are most commonly implicated in warm 
AIHA.2–5,10,11,13,14 Patients frequently have multiple anti-Rh 
antibodies or panreactive Rh antibodies, but having only 
anti-D  is rare in AIHA.15
There are case reports of patients developing anti-D 
after solid-organ transplant, although these are not true 
autoantibodies as they were passively transferred by donor 
lymphocytes.16 Autoantibodies to D have been found in the 
setting of myelodysplasia17 and as a paraneoplastic syndrome 
associated with breast carcinoma and ovarian teratoma.18,19 
There was an additional case report of IgM anti-D in the 
setting of non-Hodgkin lymphoma.20 To date, there is only one 
case of primary AIHA caused by anti-D in an adult patient.15 
To our knowledge, the case presented here is a unique case of 
primary AIHA with an IgG antibody toward the D antigen in 
a pediatric patient.
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